TITLE

Bromocriptine in Diabetes Mellitus - A Review

AUTHOR(S)
Pandita, Aakriti; Azher, Idrees
PUB. DATE
January 2013
SOURCE
Asian Student Medical Journal;2013, Vol. 13 Issue 6, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article presents information on the approval of the drug QR-bromocriptine by the U.S. Food and Drug Administration (FDA) for the treatment of type 2 diabetes mellitus. It mentions that the drug is an antidiabetic that helps in reducing plasma glucose, triglycerides and cardiovascular events. It also offers brief information on the drug's mode of action, dosage and utility in India.
ACCESSION #
85851480

 

Related Articles

  • FDA actions.  // Primary Care Reports;Jul2011 Pharmacology Watch, p2 

    The article reports on several measures taken by the U.S. Food and Drug Administration (FDA) as of July 2011. Linagliptin has received approval for use in treating adults with type 2 diabetes. The non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine has been approved for use in...

  • FDA Dings Takeda/Furiex Type II Diabetes Duo. Shaffer, Catherine // BioWorld Today;4/27/2012, Vol. 23 Issue 82, p3 

    The article reports on the complete response letter issued by the U.S. Food and Drug Administration (FDA) to Takeda Pharmaceutical Co. Ltd. and Furiex Pharmaceuticals Inc. regarding new drug applications for their Type II diabetes products. These products are alogliptin and fixed-dose...

  • NEWSLINE.  // MPR - Pharmacist's Edition;Fall2014, Vol. 8 Issue 3, pA10 

    The article offers news briefs related to the pharmaceutical industry in the U.S. The Invokamet tablets have been approved by the Food and Drug Administration (FDA) for the treatment of type 2 diabetes mellitus. Tramadol opioid analgesic has been declared by the Drug Enforcement Administration...

  • First in DPP-4 inhibitor class cleared for diabetes.  // Drug Topics;11/20/2006, Vol. 150 Issue 22, p18 

    The article reports on the U.S. Food and Drug Administration's approval of Merck & Co.'s sitagliptin, Januvia, as both a monotherapy and an add-on treatment to improve glycemic control in Type 2 diabetes. According to Merck, sitagliptin inhibits the action of dipeptidyl peptidase-4 and slows...

  • Combination drug offers new option for diabetes. Belden, Heidi // Drug Topics;5/7/2007, Vol. 151 Issue 9, p20 

    The article reports that the U.S. Food and Drug Administration has approved Janumet from Merck and Co. In. for the treatment of type 2 diabetes. Janumet is a two-in-one product containing metformin and sitagliptin which can also be used in patients already taking the two drugs separately and...

  • New Options in Insulin Therapy. SARAIYA, NIDHI; MARTIN, SPENCER T. // Connecticut Medicine;Oct2015, Vol. 79 Issue 9, p553 

    The article presents a study on the options of using insulin therapy for the treatment of type 1 diabetes mellitus (TlDM) and type 2 diabetes mellitus (T2DM). Topics discussed include the approval of the insulin glargine 300 units/mL formulation by the U.S. Food and Drug Administration (FDA),...

  • product showcase.  // Pharmacy Today;Jan2011, Vol. 17 Issue 1, p30 

    The article offers updates related to pharmacology in the U.S. Bromocriptine, a dopamine receptor, has been approved by the Food and Drug Administration (FDA) to manage type 2 diabetes coupled with diet and exercise. Also, the FDA has approved Shire's lisdexamfetamine capsules to treat...

  • Selling Safety—Lessons From Muraglitazar. Brophy, James M. // JAMA: Journal of the American Medical Association;11/23/2005, Vol. 294 Issue 20, p2633 

    The article presents an editorial regarding the U.S. Food and Drug Administration's (FDA) approval of the drug muraglitazar, a dual-peroxisome proliferator-activated receptor for the treatment of type 2 diabetes. The FDA reviewed muraglitazar's efficacy and safety and recommended drug approval....

  • Linagliptin now FDA-approved for type 2 diabetes.  // Endocrine Today;Jun2011, Vol. 9 Issue 6, p1 

    The article reports that the U.S. Food and Drug Administration (FDA) approved the use of Linagliptin to improve blood glucose control in adult patients with type 2 diabetes.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics